Invitiation to invest in the future treatments of chronic back and leg pain

Stayble Therapeutics is now conducting a rights issue to finance further development. The proceeds will be used to complete Stayble’s new Phase 1b study in patients with herniated discs, to complete the ongoing Phase 2b study in degenerative disc disease and to fund preparations for future partnerships.

Read more about the rights issue

Get to know Stayble

Latest press releases

March 24, 2023 Regulatorisk

Today the subscription period of StaybIe Therapeutics AB’s rights issue starts

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 23, 2023 Regulatorisk

StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

What makes stayble unique?

By using STA363 in two separate projects targeting DDD and LDH respectively, Stayble has advanced to a position at the forefront of injectionbased, minimally invasive treatments for chronic back and leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by degeneration and hernia.

About Stayble

One candidate- two treatments against chronic back and leg pain

About Stayble

Treatment of degenerative disc disease (DDD)

Stayble currently has one lead R&D project, which is a one-time injectionbased treatment (STA363) for patients suffering from degenerative disc disease and is currently being evaluated in an fully recruited ongoing clinical phase 2b trial.

DDD candidate

Treatment of lumbar disc herniation (LDH)

We recently seized the opportunity to launch the development of a second project, based on the same candidate (STA363), which aims to target patients suffering from unresolved herniated discs.

LDH Candidate

Invest in the future treatment of chronic back and leg pain

Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.

Investors

Bridging the therapeutic gap

The majority of patients suffering from degenerative disc disease and unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.

Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

About Stayble